#China #Shanghai #Mabwell #Albipagrastim #Qilu Pharma

Mabwell and Qilu Pharmaceutical Forge Key Licensing Agreement for Albipagrastim alfa

Mabwell (688062.SH), a biopharmaceutical innovator renowned for its comprehensive industry chain, has now made headlines by announcing a pivotal licensing agreement with Qilu Pharmaceutical for the promising drug, Albipagrastim alfa for Injection (RD code 8MW0511). The agreement includes exclusive rights for Qilu to develop, manufacture, and commercialize this innovative therapeutic in the Greater China region, which includes the Chinese Mainland, Hong Kong, Macau, and Taiwan.

Under the terms of this partnership, Mabwell expects to gather up to RMB 500 million in initial and milestone payments, alongside royalties reaching into the double digits based on the net sales of the licensed product. This agreement represents a noteworthy advancement in Mabwell’s strategy to enhance its product portfolio and reach within the biopharmaceutical landscape.

What is Albipagrastim alfa?

Albipagrastim alfa for Injection is a recombinant protein that fuses human granulocyte-colony stimulating factor (G-CSF) with human serum albumin. This drug is designed to significantly reduce the risk of infections, particularly febrile neutropenia, among adult patients suffering from non-myeloid malignancies who are undergoing myelosuppressive chemotherapy. By targeting these vulnerable populations, Albipagrastim alfa aims to improve patient outcomes and enhance treatment adherence.

The innovation lies in its formulation. Albipagrastim alfa marks a next-generation advancement in G-CSF therapy, leveraging Mabwell’s proprietary albumin fusion platform technology. By merging high-potency recombinant G-CSF with human serum albumin, the drug benefits from an increased molecular weight, resulting in a substantial prolongation of its half-life in the body. This modification effectively minimizes the frequency of administration, offering greater convenience and improved clinical adherence compared to existing solutions like PEG-G-CSF. The use of Pichia pastoris for its production further simplifies the manufacturing process and enhances product consistency.

About Qilu Pharmaceutical

Qilu Pharmaceutical stands as one of China's leading vertically integrated pharmaceutical firms, recognized for its comprehensive capabilities in developing, manufacturing, and distributing both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). With a workforce of over 36,000 employees and 12 subsidiaries, Qilu ranks among the top three pharmaceutical companies in China. They are committed to delivering high-quality, trustworthy medicines worldwide while actively exporting to over 100 countries and regions. The company has established a robust pipeline that includes more than 300 products, with notable first-to-launch entries that speak to its innovation and market presence.

About Mabwell

Mabwell’s mission, “Explore Life, Benefit Health,” highlights its dedication to advancing biopharmaceutical innovation to meet global healthcare needs, particularly in oncology and age-related diseases. With a strategy centered on effective therapies and innovative medicines, Mabwell aims to transform complex medical challenges into tangible health solutions. Their commitment to providing accessible healthcare solutions aligns with their vision to turn innovative ideas into reality.

The announcements and agreements surrounding Albipagrastim alfa not only underscore Mabwell’s strategic progress but also signify a significant step forward in enhancing treatment options for patients battling serious health conditions. As this partnership evolves, it may set the stage for a new era of biopharmaceutical collaboration and development in the Greater China market.

Conclusion

As Mabwell and Qilu Pharmaceutical embark on this journey together, the healthcare landscape in Greater China could witness substantial advancements in the management of cancer-related complications. The successful commercialization of Albipagrastim alfa could potentially improve the lives of many patients and mark a noteworthy milestone in biopharmaceutical history.